Open AccessA phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia
Author(s) -
Mario E. Lacouture,
Hedy Dion,
Shobha Ravipaty,
Joaquín J. Jiménez,
Khampaseuth Thapa,
Eric M. Grund,
Ely Benaim,
Nikunj Tanna,
Shen Luan,
Nathaniel DiTommaso,
Niven R. Narain,
Rangaprasad Sarangarajan,
Elder Granger,
Brian Berman,
Shari Goldfarb
Publication year - 2020
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-020-06005-6
Subject(s) - medicine , tolerability , adverse effect , nausea , taxane , chemotherapy , hair loss , vomiting , regimen , breast cancer , chemotherapy regimen , cancer , surgery , dermatology
Chemotherapy-induced alopecia (CIA) negatively affects psychosocial health and quality of life (QoL). Currently, there are no approved pharmacologic agents to prevent CIA. Here, we evaluated the safety, tolerability, and potential signal of efficacy of topical calcitriol (BPM31543) on CIA prevention.